Comparison of patients with the 2 rituximab regimens for ITP
| Characteristics . | 2 fixed 1-g infusions (n = 72) . | 4 infusions, 375 mg/m2 (n = 173) . | P value . |
|---|---|---|---|
| Age (y), mean ± SD | 53 ± 20 | 51 ± 21 | .49 |
| Sex (M/F) | 25/47 | 63/110 | .8 |
| Weight (kg), mean ± SD | 74.7 ± 22.2 | 75.0 ± 20.4 | .91 |
| ITP duration | |||
| <1 y | 24 (34%) | 75 (43%) | .16 |
| ≥1 y | 47 (66%) | 97 (56%) | |
| No. of previous treatment lines, mean ± SD | 3.11 ± 1.47 | 2.66 ± 1.29 | .03 |
| Platelet count at ITP diagnosis (×109/L), mean ± SD | 29 ± 28 | 26 ± 24 | .468 |
| Lower platelet count in the month preceding the first rituximab infusion (×109/L), mean ± SD | 22 ± 26 | 18 ± 18 | .23 |
| Follow-up duration (months), mean ± SD | 22 ± 10 | 24 ± 11 | .15 |
| No. with initial response | 44 (61%) | 106 (62%) | .9 |
| No. with long-term response | 29 (40%) | 68 (39%) | .7 |
| Characteristics . | 2 fixed 1-g infusions (n = 72) . | 4 infusions, 375 mg/m2 (n = 173) . | P value . |
|---|---|---|---|
| Age (y), mean ± SD | 53 ± 20 | 51 ± 21 | .49 |
| Sex (M/F) | 25/47 | 63/110 | .8 |
| Weight (kg), mean ± SD | 74.7 ± 22.2 | 75.0 ± 20.4 | .91 |
| ITP duration | |||
| <1 y | 24 (34%) | 75 (43%) | .16 |
| ≥1 y | 47 (66%) | 97 (56%) | |
| No. of previous treatment lines, mean ± SD | 3.11 ± 1.47 | 2.66 ± 1.29 | .03 |
| Platelet count at ITP diagnosis (×109/L), mean ± SD | 29 ± 28 | 26 ± 24 | .468 |
| Lower platelet count in the month preceding the first rituximab infusion (×109/L), mean ± SD | 22 ± 26 | 18 ± 18 | .23 |
| Follow-up duration (months), mean ± SD | 22 ± 10 | 24 ± 11 | .15 |
| No. with initial response | 44 (61%) | 106 (62%) | .9 |
| No. with long-term response | 29 (40%) | 68 (39%) | .7 |